Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec erosion

Executive Summary

Substitution of generic omeprazole is 12% of total scripts, 19% of new according to Jan. 5 data, Schwarz AG CEO Klaus Veitinger reported Jan. 8 at J.P. Morgan H&Q Conference in San Francisco. Schwarz subsidiary Kudco is distributing the generic of AstraZeneca's proton pump inhibitor Prilosec to mail order operations on limited basis due to manufacturing limitations (1"The Pink Sheet" Dec. 16, 2002, p. 30). Mail order aided sweeping substitution of generic fluoxetine (Lilly's Prozac), which had 80% mail service conversion rate in one week (2"The Pink Sheet" Aug. 27, 2001, p. 8). Express Scripts' 2001 Drug Trend Report predicted that, if introduced by December, generic omeprazole market share would reach 17% by end of 2003 (3"The Pink Sheet" June 17, 2002, p. 12)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel